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ABSTRACT The PTENyMMAC1 phosphatase is a tumor
suppressor gene implicated in a wide range of human cancers.
Here we provide biochemical and functional evidence that
PTENyMMAC1 acts a negative regulator of the phosphoino-
sitide 3-kinase (PI3-kinase)yAkt pathway. PTENyMMAC1
impairs activation of endogenous Akt in cells and inhibits
phosphorylation of 4E-BP1, a downstream target of the PI3-
kinaseyAkt pathway involved in protein translation, whereas
a catalytically inactive, dominant negative PTENyMMAC1
mutant enhances 4E-BP1 phosphorylation. In addition,
PTENyMMAC1 represses gene expression in a manner that is
rescued by Akt but not PI3-kinase. Finally, higher levels of Akt
activation are observed in human prostate cancer cell lines
and xenografts lacking PTENyMMAC1 expression when com-
pared with PTENyMMAC1-positive prostate tumors or nor-
mal prostate tissue. Because constitutive activation of either
PI3-kinase or Akt is known to induce cellular transformation,
an increase in the activation of this pathway caused by
mutations in PTENyMMAC1 provides a potential mechanism
for its tumor suppressor function.
PTENyMMAC1 is a tumor suppressor gene implicated in
multiple human tumors, including cancers of the prostate,
breast, endometrium, glioblastoma, and melanoma (1–3). Loss
of PTENyMMAC1 function can occur through homozygous
gene deletion, point mutation, or loss of expression (1, 2, 4).
Several hereditary cancer-prone states such as Cowden disease
and Bannayan-Zonana syndrome are associated with germ-
line mutations in PTENyMMAC1 (5, 6), and heterozygous
disruption of PTENyMMAC1 in mice leads to tumor forma-
tion in multiple tissues (7). Overexpression of PTENyMMAC1
suppresses growth in a glioma cell line (8) and inhibits cell
migration and spreading in fibroblasts, possibly through effects
on focal adhesion kinase (9). Immunohistochemical studies
show that PTENyMMAC1 is present in the cytoplasm (4, 10),
but its precise subcellular localization is not known. PTENy
MMAC1 contains a conserved catalytic motif found in mul-
tiple tyrosine phosphatases and has been shown to dephos-
phorylate a glutamineytyrosine-rich peptide substrate as well
as the lipid second messenger phosphatidylinositol 3,4,5-
trisphosphate [PtdIns(3, 4, 5)P3] in vitro (11, 12). Because
several other protein tyrosine phosphatases can antagonize or
down-modulate specific signal transduction pathways (13–18),
it is possible that PTENyMMAC1 functions as a tumor
suppressor by a similar mechanism, but the identity of the
affected pathway(s) is unknown.
PtdIns (4)P and PtdIns (4, 5)P2 are substrates of phospho-
inositide 3-kinase (PI3-kinase), which generates PtdIns(3, 4)P2
and PtdIns(3, 4, 5)P3, respectively. PtdIns(3, 4)P2 and PtdIns(3,
4, 5)P3 participate with two other kinases, 3-phosphoinositide-
dependent kinase 1 and 2, in the activation of the seriney
threonine kinase Akt through binding its pleckstrin homology
domain (19–26). The fact that PtdIns(3, 4, 5)P3 is a substrate
for PTENyMMAC1 in vitro (12) and that PI3-kinase and Akt
both play critical roles in a variety of growth factor signaling
pathways (27–32) raises the possibility that PTENyMMAC1
functions as a tumor suppressor through negative regulation of
the PI3-kinaseyAkt pathway. Here we show that increasing the
level of PTENyMMAC1 expression in cells reduces activation
of endogenous Akt and phosphorylation of the downstream
Akt target 4E-BP1. Conversely, inhibition of PTENyMMAC1
function using a dominant negative allele enhances 4E-BP1
phosphorylation. One functional consequence of enhanced
PTENyMMAC1 expression is suppression of gene expression
from prostate-specific antigen (PSA) and cytomegalovirus
(CMV)-driven reporter constructs. PTENyMMAC1-medi-
ated repression of gene expression is rescued by activated Akt
but not by activated PI3-kinase, suggesting that PTENy
MMAC1 is positioned in a signaling pathway between PI3-
kinase and Akt. Human prostate cancer cell lines and xeno-
grafts lacking PTENyMMAC1 expression have high levels of
Akt activation compared with normal prostate tissue, whereas
those prostate cancers that retain PTENyMMAC1 expression
do not. These results are consistent with the hypothesis that the
transformation phenotype of loss of PTENyMMAC1 function
is a consequence of enhanced PI3-kinaseyAkt pathway acti-
vation.
MATERIALS AND METHODS
cDNAs and Plasmids. The PTENyMMAC1 cDNA was
obtained by PCR using primers 59-ACAGGCTCCCAGA-
CATGACA-39 and 59-TCAGACTTTTGTAATTTGTG-
TATG-39 and subcloned into the pCDNA3 expression vector
(Invitrogen) and the retrovirus vector pSRaMSVtkNeo (33).
The PTENyMMAC1 C124S cDNA was created by PCR using
primers 59-AGCAATTCACTCTAAAGCTGGAA-39 and 59-
TTCCAGCTTTAGAGTGAATTGCT-39. Both constructs
were confirmed by sequencing. The hemagglutinin (HA)-
epitope tagged cDNA encoding 4E-BP1 was prepared by PCR
using oligonucleotide primers as described (34), sequenced to
confirm its identity and subcloned into pCDNA3. The CMV-
luciferase plasmid was kindly provided by Lily Wu (University
of California, Los Angeles). The PSA promoteryenhancer
reporter construct (35), PEP expression construct (36), con-
stitutively active PI3-kinase (37), dominant negative Akt (31),
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and Myr-Akt (38) plasmids have been described. Transfections
of LNCaP cells (39) were performed by using Tfx50 according
to the manufacturer’s instructions (Promega). 293T cells were
transfected using calcium phosphate as described (40). PTENy
MMAC1 retrovirus was prepared by transient transfection of
293T cells as described (41). Rat-1 fibroblasts stably expressing
wild-type PTENyMMAC1 or PTENyMMAC1 C124S were
generated by infection with retrovirus and selection in G418
antibiotic.
RNA and Protein Analysis. RNA was prepared by using
RNAzol and determined by Northern blot analysis. PTENy
MMAC1 expression was monitored by immunoblot using
anti-PTEN antibody (4). Total endogenous Akt protein levels
were measured by immunoblot using a pan-Akt antibody (New
England Biolabs). Activated, phosphorylated Akt was mea-
sured using an antibody that specifically recognizes Ser-473
according to the manufacturer’s instructions (New England
Biolabs). Activated, phosphorylated Erk was measured by
using a phospho-Erk antibody (Promega). Total endogenous
Erk levels were measured by immunoblot using a pan-Erk
antibody (Santa Cruz Biotechnology). Expression of trans-
fected PI3-kinase was measured by immunoblot using an
anti-Myc epitope antibody 9E10. Expression of transfected
Akt was measured by immunoblot using anti-HA antibody.
Phosphorylation of 4E-BP1 was monitored by altered electro-
phoretic mobility in immunoblot assays of whole-cell lysates
using an anti-HA antibody. Immunoblot analysis for green
fluorescent protein (GFP) expression was performed on
whole-cell lysates using a commercially available antibody
(CLONTECH) according to the manufacturer’s instructions.
GFP expression also was monitored by fluorescence micros-
copy and flow cytometry.
RESULTS AND DISCUSSION
To address the possibility that PTENyMMAC1 functions as a
tumor suppressor through negative regulation of the PI3-
kinaseyAkt pathway, we asked whether modulating the level of
PTENyMMAC1 protein affected biochemical activation of
Akt. By using a phospho-specific antibody (anti-Akt Ser-473)
that recognizes only activated Akt, we found a consistent 5-fold
reduction in the level of phosphorylated endogenous Akt in
293T cells transfected with PTENyMMAC1 without signifi-
cant changes in the levels of total Akt protein (Fig. 1A). To
determine the effect of PTENyMMAC1 overexpression in
stably expressing cells, Rat-1 fibroblasts were infected with
retroviruses expressing wild-type PTENyMMAC1 or a cata-
lytically inactive mutant containing a cysteine to serine sub-
stitution at position 124 (PTENyMMAC1 C124S), a change
known to impair phosphatase activity (11). After selection for
2 weeks in G418 antibiotic, populations of fibroblasts express-
ing wild-type PTENyMMAC1, PTENyMMAC1 C124S, or
Neo alone were obtained (Fig. 1B). Cells were starved of
serum for 24 hr then challenged with serum for 30 min to
activate endogenous Akt. Serum-induced Akt activation was
severely blunted in wild-type PTENyMMAC1-expressing
Rat-1 cells but not in the Neo control cells or the PTENy
MMAC1 C124S-expressing cells (Fig. 1C). These results indi-
cate that expression of PTENyMMAC1 represses basal levels
of Akt activation and blocks growth-factor-induced Akt acti-
vation in a phosphatase-dependent fashion.
To determine whether PTENyMMAC1 expression affected
other signaling pathways, we examined the activation of Erk
kinases in the Rat-1 populations expressing wild-type PTENy
MMAC1 or PTENyMMAC1 C124S. Erk is activated by a
signaling cascade involving the Raf and Mek kinases and is not
known to be influenced by phosphoinositides (42). By using an
antibody that specifically recognizes activated, phosphorylated
Erk, we observed no significant differences in basal Erk
activation in Rat-1 cells expressing wild-type or PTENy
MMAC1 C124S (Fig. 1B). This result is consistent with
previous in vitro studies suggesting that the Erk kinases are not
substrates for the PTENyMMAC1 phosphatase (11) and
suggests that the effects of PTENyMMAC1 on Akt activation
are specific.
To determine whether the effects of PTENyMMAC1 on
Akt phosphorylation also led to down-regulation of an Akt-
dependent signal, we examined the phosphorylation status of
4E-BP1, a known biochemical target of the PI3-kinaseyAkt
pathway (34). 4E-BP1 is a translation repressor that inhibits
ribosome assembly on the 59-cap structure of mRNAs by
binding the eIF4E initiation factor (43, 44). When phosphor-
ylated, 4E-BP1 is no longer capable of binding to eIF4E and
translation of 59-capped mRNAs can proceed efficiently. As
expected, transfection of a constitutively activated allele of
PI3-kinase or Akt enhanced the level of 4E-BP1 phosphory-
lation, which is easily detected because of its slower electro-
phoretic mobility. Wild-type PTENyMMAC1 blocked the
PI3-kinase-induced band shift (Fig. 2A), whereas the catalyt-
ically inactive mutant had no effect (Fig. 2B). In contrast,
PTENyMMAC1 did not impair Akt-induced 4E-BP1 phos-
phorylation, suggesting that PTENyMMAC1 functions bio-
FIG. 1. PTENyMMAC1 impairs growth factor-induced activation
of Akt. (A) 293T cells were transfected with vector or wild-type
PTENyMMAC1. Endogenous levels of phosphorylated (Top) and
total (Bottom) Akt protein levels were measured by immunoblot using
an antibody that specifically recognizes Ser-473 (Top) and a pan-Akt
antibody (Bottom). (B) Populations of Rat-1 cells stably expressing a
Neo control vector, wild-type PTENyMMAC1 or PTENyMMAC1
C124S were established by retroviral infection and drug selection in
G418. The expression of PTENyMMAC1 was detected using an
antibody against endogenous PTENyMMAC (Top).The basal levels of
activated Erk were analyzed by using an antibody that specifically
recognizes phosphorylated, activated Erk (Middle). Total Erk protein
was measured by using a pan-Erk antibody (Bottom). (C) Whole-cell
lysates were prepared from Rat-1 cells stably expressing neo vector,
wild-type PTEN, or PTEN C124S that were starved of serum for 24
hr and after re-exposure to serum for 30 min. Phosphorylated (Top)
and total (Bottom) Akt levels were measured by immunoblot as in A.
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chemically between PI3-kinase and Akt. The effects of PTENy
MMAC1 in this assay cannot be explained by nonspecific
effects of phosphatase overexpression because another phos-
phatase PEP [proline-, glutamic acid-, serine-, and threonine-
rich (PEST)-domain phosphatase] (36) had no effect on
4E-BP1 phosphorylation (Fig. 2B).
Having established that overexpression of PTENyMMAC1
impairs biochemical activation of the Akt pathway, we asked
whether inhibiting endogenous PTENyMMAC1 function
would enhance Akt pathway activation. The catalytically in-
active PTENyMMAC1 C124S mutant, which functions as a
dominant inhibitor of wild-type PTENyMMAC1 (12) (data
not shown), activated 4E-BP1 phosphorylation in the absence
of PI3-kinase (Fig. 2B). Based on the combination of gain-of-
function studies through overexpression and loss-of-function
studies using a dominant negative allele, we conclude that
PTENyMMAC1 functions biochemically to down-regulate the
PI3-kinaseyAkt pathway.
Because unphosphorylated 4E-BP1 inhibits protein trans-
lation, we asked whether overexpression of PTENyMMAC1
led to any changes in gene expression. Because of our interest
in the role of PTENyMMAC1 in prostate cancer (4), we
performed these studies in LNCaP cells, a prostate cancer line
that lacks PTENyMMAC1 expression because of gene muta-
tion (1, 2). First we asked whether PTENyMMAC1 affected
signaling through the androgen receptor. Remarkably, wild-
type PTENyMMAC1 consistently repressed both basal and
androgen-inducible levels of the androgen-responsive PSA
promoteryenhancer, whereas the catalytically inactive PTENy
MMAC1 C124S mutant had no effect (Fig. 3A). In the course
of these experiments we also noted reduced expression of a
control plasmid used to measure transfection efficiency
(CMV-enhanced GFP) in PTENyMMAC1-transfected cells
(Fig. 3B). Similar reductions in gene expression were obtained
by using CMV-luciferase as the reporter (Fig. 3A) as well as in
U87 glioma cells (data not shown), indicating that this effect
is not specific to LNCaP cells or prostate cancer.
Because PTENyMMAC1 can suppress growth in U87 gli-
oma cells (8), one potential explanation for our results is that
PTEN-induced cellular toxicity leads to a general decrease in
gene expression. However, in a series of kinetic experiments
we observed 16- to 50-fold suppression of CMV-luciferase
within 6–18 hr after transfection (Fig. 3C). To determine
whether these effects were a consequence of cell death or
growth arrest, LNCaP cells were cotransfected with CMV-
GFP and either control vector, wild-type PTENyMMAC, or
PTENyMMAC1 C124S and analyzed by flow cytometry after
staining with propidium iodide andyor by fluorescence mi-
FIG. 2. PTENyMMAC1 blocks phosphorylation of the translation
repressor 4E-BP1, a downstream target of the PI3-kinaseyAkt path-
way. (A) 293T cells were transfected with 4E-BP1 in the presence or
absence of wild-type PTENyMMAC1 and either Myr-Akt or consti-
tutively active PI3-kinase then starved of serum for 48 hr. Phosphor-
ylation of 4E-BP1 was monitored by altered electrophoretic mobility
in immunoblot assays of whole-cell lysates using an anti-HA antibody.
Expression of PTENyMMAC1, PI3-kinase, and Myr-Akt was moni-
tored by immunoblot using anti-PTEN antibody, anti-Myc antibody,
and anti-HA antibody respectively. (B) 293T cells were transfected
with 4E-BP1 in conjunction with plasmids noted at the top of each




FIG. 3. PTENyMMAC1 suppresses gene expression from the PSA
and CMV promoters. (A) LNCaP prostate cancer cells were trans-
fected with PSA enhancer (PSE)-luciferase or CMV-luciferase in
conjunction with vector, wild-type PTEN/MMAC1 or PTENy
MMAC1 C124S. Luciferase activity in PSE luciferase-transfected cells
was analyzed 48 hr after stimulation with 1 nM concentration of the
synthetic androgen R1881 (DuPont) vs. control. CMV-luciferase-
transfected cells were not stimulated. (B) LNCaP cells were trans-
fected with CMV-enhanced GFP and vector, wild-type PTENy
MMAC1, or PTENyMMAC1 C124S and examined by fluorescence
microscopy after 48 hr. Flow cytometry analysis confirmed successful
transfection of all plates with reduced brightness in the wild-type
PTENyMMAC1-transfected cells (data not shown). (C) LNCaP cells
were transfected with CMV-luciferase and analyzed at 6 and 18 hr
after transfection. (D) LNCaP cells transfected with CMV-GFP and
vector or wild-type PTENyMMAC1 were analyzed after 48 hr for GFP
expression by immunoblot (Top) or Northern blot analysis (Middle).
28S RNA levels were measured by ethidium bromide staining. Immu-
noblot analysis for GFP protein expression was performed on whole-
cell lysates using a commercially available antibody (CLONTECH).
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croscopy at various time intervals from 6 to 48 hr after
transfection. In three independent experiments, no differences
in cell cycle profile or sub-G1 DNA content were observed at
any timepoint after gating on the green cells, nor was there any
morphologic evidence of increased apoptosis or reduced via-
bility in the wild-type PTENyMMAC1-transfected cells. The
success of the transfections was documented by expression of
GFP in '30% of the cells and by immunoblot analysis
confirming PTENyMMAC1 protein expression (data not
shown). These results indicate that the effects on gene expres-
sion are unlikely to be a consequence of PTENyMMAC1-
induced toxicity.
To determine whether PTENyMMAC1-mediated suppres-
sion of gene expression is the result of effects on transcription
or translation or both, we compared RNA and protein levels
of GFP in cells cotransfected with CMV-GFP and a control
vector or wild-type PTENyMMAC1. Wild-type PTENy
MMAC1 caused a reduction in the level of GFP mRNA and
GFP protein (Fig. 3D), indicating that the effects of PTENy
MMAC1 on gene expression are complex and may not be
mediated entirely through inhibition of translation. One pos-
sibility is that a PTENyMMAC1-mediated block to translation
impairs the synthesis of critical transcription factors, leading to
a secondary reduction in mRNA levels. Alternatively, tran-
scription from the PSA and CMV promoters used in these
studies may require the activity of a specific signaling pathway
that is the target of PTENyMMAC1 repression.
To address these general issues and the specific possibility
that the suppressive effect of PTENyMMAC1 on gene expres-
sion resulted from inhibition of the PI3-kinaseyAkt pathway,
we asked whether activated Akt could rescue cells from the
PTENyMMAC1-induced block to gene expression. Analogous
to the results from biochemical studies of 4E-BP1 phosphor-
ylation, Myr-Akt restored gene expression from CMV-
luciferase and CMV-enhanced GFP plasmids in PTENy
MMAC1-transfected cells, whereas activated PI3-kinase did
not (Fig. 4A). Similarly, expression of CMV-GFP was restored
by Myr-Akt when cells were examined by fluorescence mi-
croscopy (Fig. 4B). The kinase activity of Akt is required for
rescue from PTENyMMAC1-block to gene expression be-
cause a kinase-inactive mutant, Akt K179M, was unable to
restore gene expression (Fig. 4B). Further study is required to
determine whether the ability of Akt to rescue cells from
PTENyMMAC1-mediated repression of gene expression is
primarily a consequence of effects at the transcriptional or
translational level. Because PI3-kinase and Akt can affect gene
expression through modulation of transcription as well as
translation (45–49), it is probable that both processes play a
role. In either case, our results provide functional evidence
that the PTENyMMAC1-mediated block to gene expression
occurs downstream of PI3-kinase but proximal to Akt, pre-
cisely the point at which the putative PTENyMMAC1 sub-
strate PtdIns(3,4,5)P3 is believed to function.
One prediction based on our observations that PTENy
MMAC1 inhibits the PI3-kinaseyAkt pathway is that tumors
lacking PTENyMMAC1 function as a consequence of gene
mutation may have elevated levels of Akt activation. We tested
this hypothesis by using a set of human prostate cancer cell
lines and xenografts grown as tumors in severe combined
immunodeficient mice whose PTENyMMAC1 status has been
previously characterized (1, 2, 4). The level of activated
endogenous Akt was significantly higher in LNCaP, PC3, and
LAPC-9 tumors, three prostate cancer lines that lack PTENy
MMAC1 protein expression caused by gene mutation, when
compared with DU145 and LAPC-4 tumors, which express
wild-type PTENyMMAC1 protein, or to normal prostate
tissue (Fig. 5). All samples contained comparable levels of
total Akt protein. These results establish a correlation between
the loss of PTENyMMAC1 expression and activation of Akt
and indicate that the Akt pathway is up-regulated in human
cancers containing PTENyMMAC1 mutations.
Because loss of PTENyMMAC1 function is a common
molecular abnormality in human cancer, defining its mecha-
FIG. 4. Akt but not PI3-kinase rescues PTENyMMAC1-mediated
suppression of gene expression from the CMV promoter. (A) Trans-
fections were performed as described in Fig. 3A using CMV-luciferase
as the reporter. (B) Transfections were performed as described in Fig.
3B using CMV-enhanced GFP and visualized by fluorescence micros-
copy.
FIG. 5. Enhanced levels of Akt activation in human prostate
cancers lacking PTEN expression. Whole-cell lysates were prepared
from the human prostate cancer cell lines LNCaP, DU145, PC3, and
prostate cancer xenografts LAPC-4 and LAPC-9, which were passaged
as subcutaneous tumors in male severe combined immunodeficient
mice, and from normal human prostate tissue from three individual
patients. The levels of phosphorylated (Top) and total (Bottom) Akt
were measured by using antibodies as described in Fig. 1. The status
of the PTEN gene in each tumor is designated 1 (wild type) or 2
(mutant) as determined (1, 2, 4).
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nism of growth suppression is of critical importance. The
functional and biochemical evidence presented here from
expression studies and from analysis of human prostate tumors
demonstrate that PTENyMMAC1 functions to inhibit the
PI3-kinaseyAkt pathway, presumably through dephosphoryla-
tion of the PI3-kinase substrate PtdIns(3,4,5)P3. Because
constitutive activation of either PI3-kinase or Akt is known to
induce cellular transformation (50–53), loss of function mu-
tations in the negative regulators of this pathway are likely to
produce a similar phenotype. Therapeutic strategies that tar-
get the PI3-kinaseyAkt pathway may be particularly effective
in cancers lacking PTEN function because these tumors show
higher levels of pathway activation.
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